Xalkori Named Breakthrough Therapy for Difficult-to-Treat Rare Lymphoma
News
The U.S. Food and Drug Administration granted breakthrough therapy designation to Pfizer’s Xalkori (crizotinib) for the treatment of a subgroup of difficult-to-treat systemic anaplastic large cell lymphoma (ALCL). The FDA’s ... Read more